---
title: "Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293663023.md"
description: "Dyne Therapeutics closed an upsized public offering of 21,045,000 common shares at $20.50 per share on July 23, 2026, raising approximately $431.4 million in gross proceeds. This amount includes the full exercise of the underwriters' option to purchase additional shares. The capital will support the clinical-stage company's mission to treat genetically driven neuromuscular diseases."
datetime: "2026-07-23T20:08:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293663023.md)
  - [en](https://longbridge.com/en/news/293663023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293663023.md)
generator: "portal-rs"
---

# Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

On July 23, 2026, Dyne Therapeutics, Inc. completed an upsized underwritten public offering of 21,045,000 shares of its common stock on the Nasdaq under the symbol DYN. Each share was priced at $20.50, resulting in gross proceeds of about $431.4 million for Dyne. This figure includes 2,745,000 shares from the underwriters exercising their full option to purchase additional shares. The offering, in which all shares were sold by Dyne, aimed to support the clinical-stage company's mission of providing functional improvement for individuals with genetically driven neuromuscular diseases.

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)

## Related News & Research

- [Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN](https://longbridge.com/en/news/296188072.md)
- [Dyne Therapeutics grants new-hire equity awards for 212,500 shares under inducement plan](https://longbridge.com/en/news/296530830.md)
- [Dyne Therapeutics director Jason P. Rhodes disposes of common shares worth $67.45 million](https://longbridge.com/en/news/296148351.md)
- [Genetix kicks off sickle cell disease awareness campaign](https://longbridge.com/en/news/296468544.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**